MULTIPLE SCLEROSIS IN 2016: Immune-directed therapies in MS — efficacy and limitations

    loading  Checking for direct PDF access through Ovid

Abstract

In 2016, new highly active treatment options for relapsing-remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.

Related Topics

    loading  Loading Related Articles